First Trust Nasdaq Pharmaceuticals ETF
FTXH
15 hedge funds and large institutions have $15M invested in First Trust Nasdaq Pharmaceuticals ETF in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
42% more capital invested
Capital invested by funds: $10.6M → $15M (+$4.48M)
15% more funds holding
Funds holding: 13 → 15 (+2)
1.81% more ownership
Funds ownership: 62.32% → 64.13% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
+$2.27M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$508K |
| 3 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
+$427K |
| 4 |
LPL Financial
San Diego,
California
|
+$224K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$69.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$26.1K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$10.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
FTXH Hedge Fund Activity: Q4 2020 in Review
15 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q4 2020, worth a combined $15M — up 42% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new FTXH positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was J. Arnold Wealth Management, adding an estimated $2.27M. The largest seller was Bank of America, cutting an estimated $26.1K.
- 15 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q4 2020, up from 13 in Q3 2020.
- Funds reported $15M of First Trust Nasdaq Pharmaceuticals ETF stock for Q4 2020, up 42% quarter-over-quarter.
- 3 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q4 2020 and 1 closed out, a net change of +2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q4 2020 was J. Arnold Wealth Management, an estimated $2.27M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q4 2020 was Bank of America, an estimated $26.1K sold.
Based on aggregated 13F filings for Q4 2020.